Targeting polymer therapeutics to bone

Advanced Drug Delivery Reviews

Volumn 64, Issue 12, 2012, Pages 1189-1204

  Low, Stewart A ^a   Kopeček, Jindřich ^a,b  

^a University of Utah   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Bone fracture; Bone metastasis; Bone targeting; Cathepsin K; Drug delivery; HPMA copolymer; Hydroxyapatite; Osteoporosis; PLGA copolymer; Poly(ethylene glycol) (PEG); Prostaglandin; PTH1 34; Rheumatoid arthritis; Statins

Indexed keywords

BONE FRACTURE; BONE METASTASIS; BONE-TARGETING; HPMA COPOLYMERS; OSTEOPOROSIS; PROSTAGLANDIN; PTH1-34; RHEUMATOID ARTHRITIS; STATINS;

CONTROLLED DRUG DELIVERY; COPOLYMERS; DEVELOPING COUNTRIES; DISEASES; DRUG DELIVERY; DRUG INTERACTIONS; FUNCTIONAL POLYMERS; HYDROXYAPATITE; PATHOLOGY; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; TISSUE;

BONE;

2 (3 MERCAPTOPROPYLSULFANYL)ETHYL 1,1 BISPHOSPHONIC ACID; ACIDIC OLIGOPEPTIDE; ALENDRONIC ACID; ANABOLIC AGENT; ASPARTIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE SIALOPROTEIN; CATHEPSIN K; DENDRIMER; DENDRON; DOXORUBICIN; ESTRADIOL DERIVATIVE; ESTROGEN; GLUTAMIC ACID; HYDROXYAPATITE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOSOME; MATRIX METALLOPROTEINASE; OLIGOPEPTIDE; PACLITAXEL; PARATHYROID HORMONE[1-34]; PHOSPHONIC ACID DERIVATIVE; POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE]; POLYETHYLENEIMINE; POLYLYSINE; POLYMER; PROSTAGLANDIN; TETRACYCLINE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BONE; BONE METASTASIS; BONE MINERAL; DIARRHEA; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG TARGETING; EYE DISEASE; FLUSHING; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; LETHARGY; LOW DRUG DOSE; MICELLE; MOLECULAR WEIGHT; NEPHROTOXICITY; NONHUMAN; OSTEOARTHRITIS; OSTEOPOROSIS; PRIORITY JOURNAL; RADIOTHERAPY; REVIEW; SIDE EFFECT; TOOTH DISCOLORATION;

AGING; ANIMALS; BONE AND BONES; BONE DISEASES; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG INTERACTIONS; DRUG SYNERGISM; HUMANS; POLYMERS;

EID: 84864301792     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.01.012     Document Type: Review

References (204)

1. Shea J.E., Miller S.C. Skeletal function and structure: implications for tissue-targeted therapeutics. Adv. Drug Deliv. Rev. 2005, 57:945-957.
2. Posner A.S., Betts F. Synthetic amorphous calcium phosphate and its relation to bone mineral structure. Acc. Chem. Res. 1975, 8:273-281.
3. Wang D., Miller S.C., Shlyakhtenko L.S., Portillo A.M., Liu X.-M., Papangkorn K., Kopečková P., Lyubchenko Y., Higuchi W.I., Kopeček J. Osteotropic peptide that differentiates functional domains of the skeleton. Bioconjug. Chem. 2007, 18:1375-1378.
4. Lacey D., Timms E., Tan H.L., Kelley M., Dunstan C., Burgess T., Elliott R., Colombero A., Elliott G., Scully S. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
5. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakami A. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:3597-3602.
6. Väänänen H., Zhao H., Mulari M., Halleen J.M. The cell biology of osteoclast function. J. Cell Sci. 2000, 113:377-381.
7. Harada S. Control of osteoblast function and regulation of bone mass. Nature 2003, 423:349-355.
8. Bartl R., Frisch B., Bartl C. Osteoporosis: Diagnosis, Prevention, Therapy 2009, Springer.
9. Dempster D.W. Osteoporosis and the burden of osteoporosis-related fractures. Am. J. Manag. Care 2011, 17:S164-S169.
10. Wang D., Miller S.C., Kopečková P., Kopeček J. Bone-targeting macromolecular therapeutics. Adv. Drug Deliv. Rev. 2005, 57:1049-1076.
11. Gittens S.A., Bansal G., Zernicke R.F., Uludaǧ H. Designing proteins for bone targeting. Adv. Drug Deliv. Rev. 2005, 57:1011-1036.
12. Uludaǧ H., Yang J. Targeting systemically administered proteins to bone by bisphosphonate conjugation. Biotechnol. Prog. 2002, 18:604-611.
13. Segal E., Satchi-Fainaro R. Design and development of polymer conjugates as antiangiogenic agents. Adv. Drug Deliv. Rev. 2009, 61:1159-1176.
14. Blackwell K.A., Raisz L.G., Pilbeam C.C. Prostaglandins in bone: bad cop, good cop?. Trends Endocrinol. Metab. 2010, 21:294-301.
15. Matsuo K., Irie N. Osteoclast-osteoblast communication. Arch. Biochem. Biophys. 2008, 473:201-209.
16. Maeda H., Bharate G.Y., Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm. 2009, 71:409-419.
17. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 2010, 63:136-151.
18. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug. Chem. 2010, 21:797-802.
19. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 2010, 63:131-135.
20. Silverthorn D.U., Ober W.C., Garrison C.W., Silverthorn A.C., Johnson B.R. Human Physiology: An Integrated Approach 2004, Pearson/Benjamin Cummings, San Francisco, CA.
21. 125I polyvinylpyrrolidone through bone tissue fluid. Calcif. Tissue Res. 1977, 23:103-112.
22. Howlett C.R., Dickson M., Sheridan A.K. The fine structure of the proximal growth plate of the avian tibia: vascular supply. J. Anat. 1984, 139(Pt 1):115-132.
23. Griffin M.O., Ceballos G., Villarreal F.J. Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action. Pharmacol. Res. 2011, 63:102-107.
24. Semenkov Yu.P., Makarov E.M., Makhno V.I., Kirillov S.V. Kinetic aspects of tetracycline action on the acceptor (A) site of Escherichia coli ribosomes. FEBS Lett. 1982, 144:125-129.
25. Madison J.F. Tetracycline pigmentation of teeth. Arch. Dermatol. 1963, 88:58-59.
26. Lojodice G., Vento R., Cinque N.A., Gilli G. Effect on dental and skeletal development of administration of tetracycline in the infant. Minerva Pediatr. 1965, 17:1358-1365.
27. Bevelander G., Nakahara H., Rolle G.K. Inhibition of skeletal formation in the chick embryo following administration of tetracycline. Nature 1959, 184(Suppl. 10):728-729.
28. Perrin D.D. Binding of tetracyclines to bone. Nature 1965, 208:787-788.
29. Neale J.R., Richter N.B., Merten K.E., Grant Taylor K., Singh S., Waite L.C., Emery N.K., Smith N.B., Cai J., Pierce W.M. Bone selective effect of an estradiol conjugate with a novel tetracycline-derived bone-targeting agent. Bioorg. Med. Chem. Lett. 2009, 19:680-683.
30. Fleisch H., Russell R.G., Bisaz S., Casey P.A., Mühlbauer R.C. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution. Calcif. Tissue Res. 1968, Suppl. 10-10a.
31. Kavanagh K.L., Guo K., Dunford J.E., Wu X., Knapp S., Ebetino F.H., Rogers M.J., Russel R.G.G., Oppermann U. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:7829-7834.
32. Bradley J., Cleverly D., Burns A., Helm N., Schmid M., Marx D., Cullen D.M., Reinhardt R.A. Cyclooxygenase-2 inhibitor reduces simvastatin-induced bone morphogenetic protein-2 and bone formation in vivo. J. Periodontal Res. 2007, 42:267-273.
33. Ayukawa Y., Yasukawa E., Moriyama Y., Ogino Y., Wada H., Atsuta I., Koyano K. Local application of statin promotes bone repair through the suppression of osteoclasts and the enhancement of osteoblasts at bone-healing sites in rats. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2009, 107:336-342.
34. Ohnaka K., Shimoda S., Nawata H., Shimokawa H., Kaibuchi K., Iwamoto Y., Takayanagi R. Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem. Biophys. Res. Commun. 2001, 287:337-342.
35. Black D.M., Cummings S.R. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996, 348:1535-1541.
36. Arkader A., Morris C.D. Lymphatic spread of pagetic osteogenic sarcoma detected by bone scan. Cancer Imaging 2008, 8:131-134.
37. Lawson M.A., Xia Z., Barnett B.L., Triffitt J.T., Phipps R.J., Dunford J.E., Locklin R.M., Ebetino F.H., Russell R.G. Differences between bisphosphonates in binding affinities for hydroxyapatite. J. Biomed. Mater. Res. B Appl. Biomater. 2010, 92B:149-155.
38. Jahnke W., Henry C. An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem 2010, 5:770-776.
39. Wen D., Qing L., Harrison G., Golub E., Akintoye S. Anatomic site variability in rat skeletal uptake and desorption of fluorescently labeled bisphosphonate. Oral Dis. 2010, 4:427-432.
40. Hrubý M., Etrych T., Kučka J., Forsterová M., Ulbrich K. Hydroxybisphosphonate-containing polymeric drug-delivery systems designed for targeting into bone tissue. J. Appl. Polymer Sci. 2006, 101:3192-3201.
41. Choi S.-W., Kim J.-H. Design of surface-modified poly(d, l-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone. J. Control. Release 2007, 122:24-30.
42. Mukherjee S. Thermodynamics of bisphosphonates binding to human bone: a two-site model. J. Am. Chem. Soc. 2009, 131:8374-8375.
43. Ross R.D., Roeder R.K. Binding affinity of surface functionalized gold nanoparticles to hydroxyapatite. J. Biomed. Mater. Res. A 2011, 99A:58-66.
44. Franc G., Turrin C.O., Cavero E., Costes J.P., Duhayon C., Caminade A.M., Majoral J.P. Gem-bisphosphonate-ended group dendrimers: design and gadolinium complexing properties. Eur. J. Org. Chem. 2009, 2009:4290-4299.
45. Shao X.H., Xu J.Q., Jiao Y.P., Zhou C.R. Synthesis and characterization of an alendronate-chitosan conjugate. Appl. Mech. Mater. 2012, 140:53-57.
46. Doschak M.R., Kucharski C.M., Wright J.E., Zernicke R.F., Uludaǧ H. Improved bone delivery of osteoprotegerin by bisphosphonate conjugation in a rat model of osteoarthritis. Mol. Pharmaceutics 2009, 6:634-640.
47. Ziebart T., Pabst A., Klein M.O., Kämmerer P., Gauss L., Brüllmann D., Al-Nawas B., Walter C. Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin. Oral Investig. 2009, 15:105-111.
48. Marx R.E., Sawatari Y., Fortin M., Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J. Oral Maxillofac. Surg. 2005, 63:1567-1575.
49. Hoff A.O., Toth B.B., Altundag K., Johnson M.M., Warneke C.L., Hu M., Nooka A., Sayegh G., Desrouleaux V., Cui J., Adamus A., Gagel R.F., Hortobagyi G.N. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J. Bone Miner. Res. 2008, 23:826-836.
50. Prommer E.E. Toxicity of bisphosphonates. J. Palliat. Med. 2009, 12:1061-1065.
51. Ishizaki J. Selective drug delivery to bone using acidic oligopeptides. J. Bone Miner. Metab. 2009, 27:1-8.
52. Ouyang L., Huang W., He G., Guo L. Bone targeting prodrugs based on peptide dendrimers, synthesis and hydroxyapatite binding in vitro. Lett. Org. Chem. 2009, 6:272-277.
53. Sekido T., Sakura N., Higashi Y., Miya K., Nitta Y., Nomura M., Sawanishi H., Morito K., Masamune Y., Kasugai S., Yokogawa K., Miyamoto K. Novel drug delivery system to bone using acidic oligopeptide: pharmacokinetic characteristics and pharmacological potential. J. Drug Target. 2001, 9:111-121.
54. Neale J.R., Richter N.B., Merten K.E., Taylor K.G., Singh S., Waite L.C., Emery N.K., Smith B., Cai J., Pierce W.M. Bone selective effect of an estradiol conjugate with a novel tetracycline-derived bone-targeting agent. Bioorg. Med. Chem. Lett. 2009, 19:680-683.
55. Nasim S., Vartak A., Pierce W.M., Taylor K.G., Crooks P.A. Improved and scalable synthetic route to the synthon 17-(2-carboxyethyl)-1,3,5 (10)-estratriene: an important intermediate in the synthesis of bone-targeting estrogens. Synth. Commun. 2010, 40:772-781.
56. Nasim S., Vartak A.P., Pierce W.M., Taylor K.G., Smith N., Crooks P.A. 3-O-Phosphate ester conjugates of 17-β-O-{1-[2-carboxy-(2-hydroxy-4-methoxy-3-carboxamido) anilido]ethyl}1,3,5(10)-estratriene as novel bone-targeting agents. Bioorg. Med. Chem. Lett. 2010, 20:7450-7453.
57. Murphy M.B. Synthesis and in vitro hydroxyapatite binding of peptides conjugated to calcium-binding moieties. Biomacromolecules 2007, 8:2237-2243.
58. Wang D., Sima M., Mosley R.L., Davda J.P., Tietze N., Miller S.C., Gwilt P.R., Kopečková P., Kopeček J. Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl)methacrylamide copolymers. Mol. Pharmaceutics 2006, 3:717-725.
59. 1 to promote bone formation in aged, estrogen-deficient rats. Pharm. Res. 2008, 25:2889-2895.
60. Pan H., Sima M., Kopečková P., Wu K., Gao S., Liu J., Wang D., Miller S.C., Kopeček J. Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates. Mol. Pharmaceutics 2008, 5:548-558.
61. Noh E.M., Kim J.S., Hur H., Park B.H., Song E.K., Han M.K., Kwon K.B., Yoo W.H., Shim I.K., Lee S.J. Cordycepin inhibits IL-1β-induced MMP-1 and MMP-3 expression in rheumatoid arthritis synovial fibroblasts. Rheumatology 2009, 48:45-48.
62. Hu F., Wang C., Guo S., Sun W., Mi D., Gao Y., Zhang J., Zhu T., Yang S. δEF1 promotes osteolytic metastasis of MDA-MB-231 breast cancer cells by regulating MMP-1 expression. Biochim. Biophys. Acta, Gene Regul. Mech. 2011, 1809:200-210.
63. Nyman J.S., Lynch C.C., Perrien D.S., Thiolloy S., O'Quinn E.C., Patil C.A., Pharr G.M., Mahadevan-Jansen A., Mundy G.R. Differential effects between the loss of MMP-2 and MMP-9 on structural and tissue-level properties of bone. J. Bone Miner. Res. 2011, 26:1252-1260.
64. Takaishi H., Kimura T., Dalal S., Okada Y., D'Armiento J. Joint diseases and matrix metalloproteinases: a role for MMP-13. Curr. Pharm. Biotechnol. 2008, 9:47-54.
65. Franco G.C.N., Kajiya M., Nakanishi T., Ohta K., Rosalen P.L., Groppo F.C., Ernst C.W.O., Boyesen J.L., Bartlett J.D., Strashenko P. Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo. Exp. Cell Res. 2011, 317:1454-1464.
66. Mosig R.A., Dowling O., DiFeo A., Ramirez M.C.M., Parker I.C., Abe E., Diouri J., Aqeel A.A., Wylie J.D., Oblander S.A. Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth. Hum. Mol. Genet. 2007, 16:1113-1123.
67. Lynch C.C., Hikosaka A., Acuff H.B., Martin M.D., Kawai N., Singh R.K., Vargo-Gogola T.C., Begtrup J.L., Fingleton B. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005, 7:485-496.
68. Mun S.H., Kim H.S., Kim J.W., Ko N.Y., Kim D.K., Lee B.Y., Kim B., Won H.S., Shin H.S., Han J.W. Oral administration of curcumin suppresses production of matrix metalloproteinase (MMP)-1 and MMP-3 to ameliorate collagen-induced arthritis: inhibition of the PKCδ/JNK/c-Jun Pathway. J. Pharmacol. Sci. 2009, 111:13-21.
69. Luo X.H., Guo L.J., Shan P.F., Xie H., Wu X.P., Zhang H., Cao X.Z., Yuan L.Q., Liao E.Y. Relationship of circulating MMP-2, MMP-1, and TIMP-1 levels with bone biochemical markers and bone mineral density in postmenopausal Chinese women. Osteoporos. Int. 2006, 17:521-526.
70. Gwack C., Kim S.S., Park S.B., Son W.S., Kim Y.D., Jun E.S., Park M.H. The expression of MMP-1,-8, and-13 mRNA in the periodontal ligament of rats during tooth movement with cortical punching. Korean J.Orthod. 2008, 38:187-201.
71. Lynch C.C., Matrisian L.M. Matrix metalloproteinases as key regulators of tumor-bone interaction. Cancer Degradome 2008, 541-566.
72. Smith G.N., Mickler E.A., Hasty K.A., Brandt K.D. Specificity of inhibition of matrix metalloproteinase activity by doxycycline: relationship to structure of the enzyme. Arthritis Rheum. 1999, 42:1140-1146.
73. Georges S., Ruiz Velasco C., Trichet V., Fortun Y., Heymann D., Padrines M. Proteases and bone remodeling. Cytokine Growth Factor Rev. 2009, 20:29-41.
74. Rejmanová P., Pohl J., Baudyš M., Kostka V., Kopeček J. Polymers containing enzymatically degradable bonds. 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B. Makromol. Chem. 1983, 184:2009-2020.
75. Gao S., Lu Z.R., Petri B., Kopečková P., Kopeček J. Colon-specific 9-aminocamptothecin-HPMA copolymer conjugates containing a 1,6-elimination spacer. J. Control. Release 2006, 110:323-331.
76. Greenwald R.B., Pendri A., Conover C.D., Zhao H., Choe Y.H., Martinez A., Shum K., Guan S. Drug delivery systems employing 1,4- or 1,6-elimination: poly(ethylene glycol) prodrugs of amine-containing compounds. J. Med. Chem. 1999, 42:3657-3667.
77. Carl P.L., Chakravarty P.K., Katzenellenbogen J.A. A novel connector linkage applicable in prodrug design. J. Med. Chem. 1981, 24:479-480.
78. Toki B.E., Cerveny C.G., Wahl A.F., Senter P.D. Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugs. J. Org. Chem. 2002, 67:1866-1872.
79. de Groot F.M., Loos W.J., Koekkoek R., van Berkom L.W., Busscher G.F., Seelen A.E., Albrecht C., de Bruijn P., Scheeren H.W. Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release. J. Org. Chem. 2001, 66:8815-8830.
80. Segal E., Pan H., Ofek P., Udagawa T., Kopečková P., Kopeček J., Satchi-Fainaro R. Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS One 2009, 4:e5233.
81. Segal E., Pan H., Benayoun L., Kopečková P., Shaked Y., Kopeček J., Satchi-Fainaro R. Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances. Biomaterials 2011, 32:4450-4463.
82. Miller K., Erez R., Segal E., Shabat D., Satchi-Fainaro R. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugates. Angew. Chem. Int. Ed. 2009, 48:2949-2954.
83. Yang J., Chen H., Vlahov I.R., Cheng J.-X., Low P.S. Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:13872-13877.
84. Kurtoglu Y.E., Navath R.S., Wang B., Kannan S., Romero R., Kannan R.M. Poly(amidoamine) dendrimer-drug conjugates with disulfide linkages for intracellular drug delivery. Biomaterials 2009, 30:2112-2121.
85. Nesbitt S.A., Horton M.A. Trafficking of matrix collagens through bone-resorbing osteoclasts. Science 1997, 276:266-273.
86. Palokangas H., Mulari M., Väänänen H.K. Endocytic pathway from basal plasma membrane to the ruffled border membrane in bone-resorbing osteoclasts. J. Cell Sci. 1997, 110:1767-1780.
87. Mulari M.T.K., Zhao H.B., Lakkakorpi P.T., Väänänen H.K. Osteoclast ruffled border has distinct subdomains for secretion and degraded matrix uptake. Traffic 2003, 4:113-125.
88. Pan H., Kopečková P., Wang D., Yang J., Miller S., Kopeček J. Water-soluble HPMA copolymer-prostaglandin E1 conjugates containing a cathepsin K sensitive spacer. J. Drug Target. 2006, 14:425-435.
89. Schechter I., Berger A. On the size of active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 1967, 27:157-162.
90. Lecaille F., Choe Y., Brandt W., Li Z., Craik C.S., Brömme D. Selective inhibition of the collagenolytic activity of human cathepsin K by altering its S2 subsite specificity. Biochemistry 2002, 41:8447-8454.
91. Rejmanová P., Kopeček J., Duncan R., Lloyd J.B. Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers. Biomaterials 1985, 6:45-48.
92. Kopeček J., Rejmanová P., Chytrý V. Polymers containing enzymatically degradable bonds. I. Chymotrypsin catalyzed hydrolysis of p-nitroanilides of phenylalanine and tyrosine attached to side-chains of copolymers of N-(2-hydroxypropyl)methacrylamide. Makromol. Chem. 1981, 182:799-809.
93. Pan H., Liu J., Dong Y., Sima M., Kopečková P., Brandi M.L., Kopeček J. Release of prostaglandin E1 from N-(2-Hydroxypropyl)methacrylamide copolymer conjugates by bone cells. Macromol. Biosci. 2008, 8:599-605.
94. Zhang S., Wright J.E.I., Ozber N., Uludaǧ H. The interaction of cationic polymers and their bisphosphonate derivatives with hydroxyapatite. Macromol. Biosci. 2007, 7:656-670.
95. Wen Y., Pan S., Luo X., Zhang X., Zhang W., Feng M. A biodegradable low molecular weight polyethylenimine derivative as low toxicity and efficient gene vector. Bioconjug. Chem. 2009, 20:322-332.
96. Aravindan L., Bicknell K.A., Brooks G., Khutoryanskiy V.V., Williams A.C. Effect of acyl chain length on transfection efficiency and toxicity of polyethylenimine. Int. J. Pharm. 2009, 378:201-210.
97. Jansen D.R., Rijn Zeevaart J., Denkova A., Kolar Z.I., Krijger G.C. Hydroxyapatite chemisorption of N, N', N'-trimethylenephosphonate-poly(ethyleneimine) (PEI-MP) combined with Sn2+ or Sn4+. Langmuir 2009, 25:2790-2796.
98. Jansen D.R., Krijger G.C., Wagener J., Senwedi R.M., Gabanamotse K., Kgadiete M., Kolar Z.I., Zeevaart J.R. Blood plasma model predictions for the proposed bone-seeking radiopharmaceutical [117mSn]Sn(IV)-N, N', N'-trimethylenephosphonate-poly(ethyleneimine). J. Inorg. Biochem. 2009, 103:1265-1272.
99. Yang J., Luo K., Pan H., Kopečková P., Kopeček J. Synthesis of biodegradable multiblock copolymers by click coupling of RAFT-generated heterotelechelic polyHPMA conjugates. React. Funct. Polym. 2011, 71:294-302.
100. Pan H., Yang J., Kopečková P., Kopeček J. Backbone degradable multiblock HPMA copolymer conjugates via RAFT polymerization and thiol-ene coupling reaction. Biomacromolecules 2011, 12:247-252.
101. Luo K., Yang J., Kopečková P., Kopeček J. Biodegradable multiblock N-(2-hydroxypropyl)methacrylamide copolymers via reversible addition-fragmentation chain transfer polymerization and click chemistry. Macromolecules 2011, 44:2481-2488.
102. Talelli M., Rijcken C.J.F., van Nostrum C.F., Storm G., Hennink W.E. Micelles based on HPMA copolymers. Adv. Drug Deliv. Rev. 2010, 62:231-239.
103. Krimmer S., Pan H., Liu J., Yang J., Kopeček J. Synthesis and characterization of poly(ε-caprolactone)-block-poly[N-(2-hydroxypropyl)methacrylamide] micelles for drug delivery. Macromol. Biosci. 2011, 11:1041-1051.
104. Wang D., Kopečková J.P., Minko T., Nanayakkara V., Kopeček J. Synthesis of starlike N-(2-hydroxypropyl)methacrylamide copolymers: potential drug carriers. Biomacromolecules 2000, 1:313-319.
105. Korzhikov V.A., Diederichs S., Nazarova O.V., Vlakh E.G., Kasper C., Panarin E.V., Tennikova T.B. Water-soluble aldehyde-bearing polymers of 2-deoxy-2-methacrylamido-d-glucose for bone tissue engineering. J. Appl. Polym. Sci. 2008, 108:2386-2397.
106. Hein C.D., Liu X.M., Chen F., Cullen D.M., Wang D. The synthesis of a multiblock ostotropic polyrotaxane by copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition. Macromol. Biosci. 2010, 10:1544-1556.
107. Wang G., Babadagli M.E., Uludaǧ H. Bisphosphonate-derivatized liposomes to control drug release from collagen/hydroxyapatite scaffolds. Mol. Pharmaceutics 2011, 8:1025-1034.
108. Li L.Y., He W.D., Li J., Zhang B.Y., Pan T.T., Sun X.L., Ding Z.L. Shell-cross-linked micelles from PNIPAM-b-(PLL)2Y-shaped miktoarm star copolymer as drug carriers. Biomacromolecules 2010, 11:1882-1890.
109. Hengst V., Oussoren C., Kissel T., Storm G. Bone targeting potential of bisphosphonate-targeted liposomes: preparation, characterization and hydroxyapatite binding in vitro. Int. J. Pharm. 2007, 331:224-227.
110. van den Hoven J.M., Van Tomme S.R., Metselaar J.M., Nuijen B., Beijnen J.H., Storm G. Liposomal drug formulations in the treatment of rheumatoid arthritis. Mol. Pharmaceutics 2011, 8:1002-1005.
111. Cenni E., Granchi D., Avnet S., Fotia C., Salerno M., Micieli D., Sarpietro M.G., Pignatello R., Castelli F., Baldini N. Biocompatibility of poly(d, l-lactide-co-glycolide) nanoparticles conjugated with alendronate. Biomaterials 2008, 29:1400-1411.
112. Salerno M., Cenni E., Fotia C., Avnet S., Granchi D., Castelli F., Micieli D., Pignatello R., Capulli M., Rucci N., Angelucci A., Del Fattore A., Teti A., Zini N., Giunti A., Baldini N. Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases. Curr. Cancer Drug Targets 2010, 10:649-659.
113. Wischke C., Zhang Y., Mittal S., Schwendeman S.P. Development of PLGA-based injectable delivery systems for hydrophobic fenretinide. Pharm. Res. 2010, 27:2063-2074.
114. Faisant N., Siepmann J., Benoit J.P. PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release. Eur. J. Pharm. Sci. 2002, 15:355-366.
115. Mundargi R.C., Babu V.R., Rangaswamy V., Patel P., Aminabhavi T.M. Nano/micro technologies for delivering macromolecular therapeutics using poly(d, l-lactide-co-glycolide) and its derivatives. J. Control. Release 2008, 125:193-209.
116. Ozcan I., Bouchemal K., Segura-Sánchez F., Ozer O., Güneri T., Ponchel G. Synthesis and characterization of surface-modified PBLG nanoparticles for bone targeting: in vitro and in vivo evaluations. J. Pharm. Sci. 2011, 100:4877-4887.
117. Wang G., Kucharski C., Lin X., Uludaǧ H. Bisphosphonate-coated BSA nanoparticles lack bone targeting after systemic administration. J. Drug Target. 2010, 18:611-626.
118. Bai S., Thomas C., Rawat A., Ahsan F. Recent progress in dendrimer-based nanocarriers. Crit. Rev. Ther. Drug Carrier Syst. 2006, 23:437-495.
119. Ouyang L., Pan J., Zhang Y., Guo L. Synthesis of second-and third-generation Asp oligopeptide conjugated dendrimers for bone-targeting drug delivery. Synth. Commun. 2009, 39:4039-4052.
120. Clementi C., Miller K., Mero A., Satchi-Fainaro R., Pasut G. Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms. Mol. Pharmaceutics 2011, 8:1063-1072.
121. Xiao K., Li Y., Luo J., Lee J.S., Xiao W., Gonik A.M., Agarwai R.G., Lam K.S. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials 2011, 32:3435-3446.
122. Christensen K., Doblhammer G., Rau R., Vaupel J.W. Ageing populations: the challenges ahead. Lancet 2009, 374:1196-1208.
123. Yuan F., Quan L.D., Cui L., Goldring S., Wang D. Development of macromolecular prodrug for rheumatoid arthritis. Adv. Drug Deliv. Rev. 2012, 64:1205-1219. (this volume).
124. Wang Y., Grainger D.W. RNA therapeutics targeting osteoclast-mediated excessive bone resorption. Adv. Drug Deliv. Rev. 2012, 64:1341-1357. (this issue).
125. Osteoporosis information available at, Accessed September. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001400.
126. Thompson S.K., Halbert S.M., Bossard M.J., Tomaszek T.A., Levy M.A., Zhao B., Smith W.W., Abdel-Meguid S.S., Janson C.A., D'Alessio K.J., McQueeney M.S., Amegadzie B.Y., Hanning C.R., DesJarlais R.L., Briand J., Sarkar S.K., Huddleston M.J., Ijames C.F., Carr S.A., Garnes K.T., Shu A., Heys R.J., Bradbeer J., Zembryki D., Lee-Rykaczeweski L., James I.E., Lark M.W., Drake F.H., Gowen M., Cleason J.G., Verber D.F. Design of potent and selective human cathepsin K inhibitors that span the active site. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:14249-14254.
127. Wang D., Li W., Pechar M., Kopečková P., Brömme D., Kopeček J. Cathepsin K inhibitor-polymer conjugates: potential drugs for the treatment of osteoporosis and rheumatoid arthritis. Int. J. Pharm. 2004, 277:73-79.
128. Wang D., Pechar M., Li W., Kopečková P., Brömme D., Kopeček J. Inhibition of cathepsin K with lysosomotropic macromolecular inhibitors. Biochemistry 2002, 41:8849-8859.
129. Thompson S.K., Smith W.W., Zhao B., Halbert S.M., Tomaszek T.A., Tew D.G., Levy M.A., Janson C.A., D'Alessio K.J., McQueney M.S., Kurdyla J., Jones C.S., DesJarlais R.L., Abdel-Meguid S.S., Veber D.F. Structure-based design of cathepsin K inhibitors containing a benzyloxy-substituted benzoyl peptidomimetic. J. Med. Chem. 1998, 41:3923-3927.
130. Tanaka S. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol. Rev. 2005, 208:30-49.
131. Body J.J., Gaich G.A., Scheele W.H., Kulkarni P.M., Miller P.D., Peretz A., Dore R.K., Correa-Rotter R., Papaioannou A., Cumming D.C. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 2002, 87:4528-4535.
132. Okazaki R. Osteosarcoma in rats receiving long-term PTH injection. Clin. Calcium 2003, 13:42-44.
133. Chikazu D., Fujikawa Y., Fujihara H., Suenaga H., Saijo H., Ohkubo K., Ohkubo T., Ogasawara T., Mori Y., Iino M., Takato T. Cyclooxygenase-2 activity is important in craniofacial fracture repair. Int. J. Oral Maxillofac. Surg. 2011, 40:322-326.
134. Gerstenfeld L.C., Einhorn T.A. COX inhibitors and their effects on bone healing. Expert Opin. Drug Saf. 2004, 3:131-136.
135. Vuolteenaho K., Moilanen T., Moilanen E. Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process. Basic Clin. Pharmacol. Toxicol. 2008, 102:10-14.
136. Glassman S.D., Rose S.M., Dimar J.R., Puno R.M., Campbell M.J., Johnson J.R. The effect of postoperative nonsteroidal anti-inflammatory drug administration on spinal fusion. Spine 1998, 23:834-838.
137. Giannoudis P., MacDonald D., Matthews S., Smith R., Furlong A., De Boer P. Nonunion of the femoral diaphysis: the influence of reaming and non-steroidal anti-inflammatory drugs. J. Bone Joint Surg. 2000, 82:655-658.
138. Li M., Ke H.Z., Qi H., Healy D.R., Li Y., Crawford D.T., Paralkar V.M., Owen T.A., Cameron K.O., Lefker B.A. A novel, non-prostanoid EP2 receptor-selective prostaglandin E2 agonist stimulates local bone formation and enhances fracture healing. J. Bone Miner. Res. 2003, 18:2033-2042.
139. Hirata M., Harada S., Matsumoto C., Takita M., Miyaura C., Inada M. Role of prostaglandin E in receptor activator of nuclear factor-κB ligand (RANKL) expression in osteoblasts induced by cell adhesion to bone marrow B-lymphocytes. J. Health Sci. 2009, 55:832-837.
140. Tsutsumi R., Xie C., Wei X., Zhang M., Zhang X., Flick L.M., Schwarz E.M., O'Keefe R.J. PGE2 signaling through the EP4 receptor on fibroblasts upregulates RANKL and stimulates osteolysis. J. Bone Miner. Res. 2009, 24:1753-1762.
141. Park J.Y., Bae M., Cheon H.G., Kim S.S., Hong J.M., Kim T.H., Choi J.Y., Kim S.H., Lim J., Choi C.H. A novel PPAR [gamma] agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways. Biochem. Biophys. Res. Commun. 2009, 378:645-649.
142. Idris A., Mrak E., Greig I., Guidobono F., Ralston S.H., van't Hof R. ABD56 causes osteoclast apoptosis by inhibiting the NFκB and ERK pathways. Biochem. Biophys. Res. Commun. 2008, 371:94-98.
143. Tsai H.Y., Lin H.Y., Fong Y.C., Wu J.B., Chen Y.F., Tsuzuki M., Tang C.H. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-κB pathway. Eur. J. Pharmacol. 2008, 588:124-133.
144. Minamizaki T., Yoshiko Y., Kozai K., Aubin J.E., Maeda N. EP2 and EP4 receptors differentially mediate MAPK pathways underlying anabolic actions of prostaglandin E2 on bone formation in rat calvaria cell cultures. Bone 2009, 44:1177-1185.
145. Gil L., Han Y., Opas E.E., Rodan G.A., Ruel R., Seedor J.G., Tyler P.C., Young R.N. Prostaglandin E2-bisphosphonate conjugates: potential agents for treatment of osteoporosis. Bioorg. Med. Chem. 1999, 7:901-919.
146. Kamolratanakul P., Hayata T., Ezura Y., Kawamata A., Hayashi C., Yamamoto Y., Hemmi H., Nagao M., Hanyu R., Natomi T., Nakamoto T., Amagasa T., Akyoshi K., Noda M. Nanogel-based scaffold delivery of prostaglandin E2 receptor (EP4) specific agonist in combination with low dosage of growth factor heals critical size bone defect. Arthritis Rheum. 2010, 10:1-11.
147. Fromigue O., Hay E., Modrowski D., Bouvet S., Jacquel A., Auberger P., Marie P.J. RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ. 2006, 13:1845-1856.
148. Kanazawa I., Yamaguchi T., Yano S., Yamauchi M., Sugimoto T. Activation of AMP kinase and inhibition of Rho kinase induce the mineralization of osteoblastic MC3T3-E1 cells through endothelial NOS and BMP-2 expression. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E139-E146.
149. Lee Y., Liu X., Nawshad A., Marx D.B., Wang D., Reinhardt R.A. Role of prostaglandin pathway and alendronate-based carriers to enhance statin-induced bone. Mol. Pharmaceutics 2011, 8:1035-1042.
150. Midy V., Plouët J. Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts. Biochem. Biophys. Res. Commun. 1994, 199:380-386.
151. Wong R.W.K., Rabie A.B.M. Early healing pattern of statin-induced osteogenesis. Br. J. Oral Maxillofac. Surg. 2005, 43:46-50.
152. Uzzan B., Cohen R., Nicolas P., Cucherat M., Perret G.Y. Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 2007, 40:1581-1587.
153. Yue J. Statins and bone health in postmenopausal women: a systematic review of randomized controlled trials. Menopause 2010, 17:1071-1079.
154. Moriyama Y., Ayukawa Y., Ogino Y., Atsuta I., Todo M., Takao Y., Koyano K. Local application of fluvastatin improves peri-implant bone quantity and mechanical properties: a rodent study. Acta Biomater. 2010, 6:1610-1618.
155. Stein D., Lee Y., Schmid M.J., Killpack B., Genrich M.A., Narayana N., Marx D.B., Cullen D.M., Reinhardt R.A. Local simvastatin effects on mandibular bone growth and inflammation. J. Periodontol. 2005, 76:1861-1870.
156. Pauly S., Luttosch F., Morawski M., Haas N., Schmidmaier G., Wildemann B. Simvastatin locally applied from a biodegradable coating of osteosynthetic implants improves fracture healing comparable to BMP-2 application. Bone 2009, 45:505-511.
157. Masuzaki T., Ayukawa Y., Moriyama Y., Jinno Y., Atsuta I., Ogino Y., Koyano K. The effect of a single remote injection of statin-impregnated poly (lactic-co-glycolic acid) microspheres on osteogenesis around titanium implants in rat tibia. Biomaterials 2010, 31:3327-3334.
158. Lee Y., Schmid M.J., Marx D.B., Beatty M.W., Cullen D.M., Collins M.E., Reinhardt R.A. The effect of local simvastatin delivery strategies on mandibular bone formation in vivo. Biomaterials 2008, 29:1940-1949.
159. Chikazu D., Li X., Kawaguchi H., Sakuma Y., Voznesensky O.S., Adams D.J., Xu M., Hoshio K., Katavic V., Hershman H.R., Raisz L.G., Pilbeam C.C. Bone morphogenetic protein 2 induces cyclo-oxygenase 2 in osteoblasts via a Cbfal binding site: role in effects of bone morphogenetic protein 2 in vitro and in vivo. J. Bone Miner. Res. 2002, 17:1430-1440.
160. Blackwell K.A., Hortschansky P., Sanovic S., Choudhary S., Raisz L.G., Pilbeam C.C. Bone morphogenetic protein 2 enhances PGE2 stimulated osteoclast formation in murine bone marrow cultures. Prostaglandins Other Lipid Mediat. 2009, 90:76-80.
161. Mummaneni P.V., Pan J., Haid R.W., Rodts G.E. Contribution of recombinant human bone morphogenetic protein-2 to the rapid creation of interbody fusion when used in transforaminal lumbar interbody fusion: a preliminary report. J. Neurosurg. Spine 2004, 1:19-23.
162. Schwender J.D., Holly L.T., Rouben D.P., Foley K.T. Minimally invasive transforaminal lumbar interbody fusion (TLIF): technical feasibility and initial results. J. Spinal Disord. Tech. 2005, 18(Suppl):S1-S6.
163. Baskin D.S., Ryan P., Sonntag V., Westmark R., Widmayer M.A. A prospective, randomized, controlled cervical fusion study using recombinant human bone morphogenetic protein-2 with the CORNERSTONE-SR allograft ring and the ATLANTIS anterior cervical plate. Spine 2003, 28:1219-1224. discussion 1225.
164. Riedel G.E., Valentin-Opran A. Clinical evaluation of rhBMP-2/ACS in orthopedic trauma: a progress report. Orthopedics 1999, 22:663-665.
165. Govender S., Csimma C., Genant H.K., Valentin-Opran A. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J. Bone Joint Surg. Am. 2002, 84-A:2123-2134.
166. Boyne P.J., Marx R.E., Nevins M., Triplett G., Lazaro E., Lilly L.C., Alder M. A feasibility study evaluating rhBMP-2/absorbable collagen sponge for maxillary sinus floor augmentation. Int. J. Periodontics Restorative Dent. 1997, 17:11-25.
167. Haid R.W., Branch C.L., Alexander J.T., Burkus J.K. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages. Spine J. 2004, 4:527-538. discussion 538-539.
168. Katayama Y., Matsuyama Y., Yoshihara H., Sakai Y., Nakamura H., Imagama S., Ito Z., Wakao N., Kamiya M., Yukawa Y. Clinical and radiographic outcomes of posterolateral lumbar spine fusion in humans using recombinant human bone morphogenetic protein-2: an average five-year follow-up study. Int. Orthop. 2009, 33:1061-1067.
169. Triplett R.G., Nevins M., Marx R.E., Spagnoli D.B., Oates T.W., Moy P.K., Boyne P.J. Pivotal, randomized, parallel evaluation of recombinant human bone morphogenetic protein-2/absorbable collagen sponge and autogenous bone graft for maxillary sinus floor augmentation. J. Oral Maxillofac. Surg. 2009, 67:1947-1960.
170. Shen W. Interaction between macrophages, TGF-β1, and the COX-2 pathway during the inflammatory phase of skeletal muscle healing after injury. J. Cell. Physiol. 2008, 214:405-412.
171. Niu Z., Wang L., Hu X., Wang H., Ouyang J., Huang W., Yu L., Qui X. Promotion effect of nuclear factor kappa B p65 on early fracture healing of rat radius by elevating prostaglandins E2 production and regulating inhibitor of DNA binding 2 protein expression. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2011, 25:569-574.
172. Yasui T., Kadono Y., Nakamura M., Oshima Y., Matsumoto T., Masuda H., Hirose J., Omata Y., Yasuda H., Imamura T., Nakamura K., Tanaka S. Regulation of RANKL-induced osteoclastogenesis by TGF-β through molecular interaction between Smad3 and Traf6. J. Bone Miner. Res. 2011, 26:1447-1456.
173. Gingery A., Bradley E.W., Pederson L., Ruan M., Horwood N.J., Oursler M.J. TGFβ coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival. Exp. Cell Res. 2008, 314:2725-2738.
174. Houde N., Chamoux E., Bisson M., Roux S. Transforming growth factor-beta1 (TGF-β1) induces human osteoclast apoptosis by up-regulating Bim. J. Biol. Chem. 2009, 284:23397-23404.
175. Peterson M.C., Riggs M.M. A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling. Bone 2010, 46:49-63.
176. Choudhary S., Huang H., Raisz L., Pilbeam C. Anabolic effects of PTH in cyclooxygenase-2 knockout osteoblasts in vitro. Biochem. Biophys. Res. Commun. 2008, 372:536-541.
177. Huang H., Chikazu D., Voznesensky O.S., Herschman H.R., Kream B.E., Drissi H., Pilbeam C.C. Parathyroid hormone induction of cyclooxygenase-2 in murine osteoblasts: role of the calcium-calcineurin-NFAT pathway. J. Bone Miner. Res. 2010, 25:819-829.
178. Schnoke M., Midura S.B., Midura R.J. Parathyroid hormone suppresses osteoblast apoptosis by augmenting DNA repair. Bone 2009, 45:590-602.
179. Tintut Y., Parhami F., Le V., Karsenty G., Demer L.L. Inhibition of osteoblast-specific transcription factor Cbfa1 by the cAMP pathway in osteoblastic cells. J. Biol. Chem. 1999, 274:28875-28879.
180. Zhao M., Qiao M., Oyajobi B.O., Mundy G.R., Chen D. E3 ubiquitin ligase Smurf1 mediates core-binding factor α1/Runx2 degradation and plays a specific role in osteoblast differentiation. J. Biol. Chem. 2003, 278:27939-27944.
181. Murray E.J.B., Bentley G.V., Grisanti M.S., Murray S.S. The ubiquitin-proteasome system and cellular proliferation and regulation in osteoblastic cells. Exp. Cell Res. 1998, 242:460-469.
182. Bellido T., Ali A.A., Plotkin L.I., Fu Q., Gubrij I., Roberson P.K., Weinstein R.S., O'Brien C.A., Manolagas S.C., Jilka R.L. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. J. Biol. Chem. 2003, 278:50259-50272.
183. Jilka R.L. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 2007, 40:1434-1446.
184. Zhang S., Gangal G., Uludaǧ H. "Magic bullets" for bone diseases: progress in rational design of bone-seeking medicinal agents. Chem. Soc. Rev. 2007, 36:507-531.
185. Bansal G., Wright J.E., Kucharski C., Uludaǧ H. A dendritic tetra(bisphosphonic acid) for improved targeting of proteins to bone. Angew. Chem. Int. Ed. 2005, 44:3710-3714.
186. Doschak M.R., Kucharski C.M., Wright J.E.I., Zernicke R.F., Uludaǧ H. Improved bone delivery of osteoprotegerin by bisphosphonate conjugation in a rat model of osteoarthritis. Mol. Pharmaceutics 2009, 6:634-640.
187. Vaibhav B., Nilesh P., Vikram S., Anshul C. Bone morphogenic protein and its application in trauma cases: a current concept update. Injury 2007, 38:1227-1235.
188. Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals. Nat. Drug Disc. Rev. 2003, 2:214-221.
189. Kamei S., Kopeček J. Prolonged blood circulation in rats of nanospheres surface-modified with semitelechelic poly[N-(2-hydroxypropyl)methacrylamide]. Pharm. Res. 1995, 12:663-668.
190. Clines G.A., Guise T.A. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr. Relat. Cancer 2005, 12:549-583.
191. Schajnovitz A., Itkin T., D'Uva G., Kalinkovich A., Golan K., Ludin A., Cohen D., Shulman Z., Avigdor A., Nagler A. CXCL12 secretion by bone marrow stromal cells is dependent on cell contact and mediated by connexin-43 and connexin-45 gap junctions. Nat. Immunol. 2011, 12:391-398.
192. Sugiyama T., Kohara H., Noda M., Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006, 25:977-988.
193. Akashi T., Koizumi K., Tsuneyama K., Saiki I., Takano Y., Fuse H. Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer Sci. 2008, 99:539-542.
194. Chinni S.R., Yamamoto H., Dong Z., Sabbota A., Bonfil R.D., Cher M.L. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol. Cancer Res. 2008, 6:446-457.
195. Liang Z., Yoon Y., Votaw J., Goodman M.M., Williams L., Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 2005, 65:967-971.
196. Burdick M.J., Sartor O. Bone-targeted therapy in metastatic prostate cancer: osteoclast inhibitors and bone-seeking radiopharmaceuticals. Drug Disc. Today. Ther. Strat. 2010, 7:23-29.
197. Kawatani M. Osteoclast-targeting small molecules for the treatment of neoplastic bone metastases. Cancer Sci. 2009, 100:1999-2005.
198. Saad F., Lipton A. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat. Rev. 2010, 36:177-184.
199. Miller K., Erez R., Segal E., Shabat D., Satchi-Fainaro R. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew. Chem. Int. Ed. 2009, 48:2949-2954.
200. Miller K., Eldar-Boock A., Polyak D., Segal E., Benayoun L., Shaked Y., Satchi-Fainaro R. Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model. Mol. Pharmaceutics 2011, 8:1052-1062.
201. Bhargava P., Marshall J.L., Rizvi N., Dahut W., Yoe J., Figuera M., Phipps K., Ong V.S., Kato A., Hawkins M.J. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin. Cancer Res. 1999, 5:1989-1995.
202. 131I-Labeled bisphosphonates with high in vivo stability and bone accumulation. J. Nucl. Med. 1999, 40:1197-1203.
203. 90Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases. Nucl. Med. Biol. 2009, 36:129-135.
204. Hambardzumyan D., Becher O.J., Rosenblum M.K., Pandolfi P.P., Manova-Todorova K., Holland E.C. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev. 2008, 22:436-448.